Antibody-drug conjugates (ADCs) comprise an antibody, a linker, and a cytotoxic active payload. Compared to traditional chemotherapy, ADCs that target tumors are expected to mitigate systemic toxic effects, provide a wider therapeuticRead More…
New Highlights of ADC Targeting Intracellular Antigens—TCRm-ADC
Intracellular proteins can be degraded, processed, and presented on the cell surface in complex with MHC molecules (HLA), which can be specifically recognized by TCR (Figure 1). Antibodies that recognize pMHC likeRead More…
Key Points of ADC Optimization Strategy
Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…
New Paradigm—Small Nucleic Acid Antibody Conjugates
Nucleic acid drugs are a frontier field in the development of biomedicine, and the targeted delivery system of nucleic acid drugs is both a difficult and important point. At present, small nucleicRead More…
ADC Drugs on the Market: An Overview
Antibody-drug conjugates, often referred to as ADCs, are a type of dual-targeted therapeutic. They consist of three key components: an antibody, a payload, and a linker. The antibody determines the target disease,Read More…
The Development Trends of the Next Generation of ADC Drugs
The development trends of the next generation of ADC (antibody-drug conjugate) drugs can be observed to show improved specificity and cytotoxicity compared to earlier generations, driven by technological advancements. However, it’s importantRead More…
Four Classic Fixed-point Coupling Techniques for ADC
ADC (antibody-drug conjugate) has emerged as a promising class of anti-cancer drugs, with over a dozen ADC drugs currently approved for the treatment of various types of cancer patients. Traditional ADCs utilizeRead More…
How to Optimize the Safety Profile of ADC Drugs?
Optimization Strategies for Dose Adjustment Due to the dose-dependent nature of adverse reactions in ADC therapies, optimizing safety can be achieved through dose adjustment strategies. These include setting dose limits, maximum treatmentRead More…
A General Review of ADC Adverse Reactions Published
In recent years, the development of antibody-drug conjugate (ADC) therapies has flourished, leading to significant advancements in treating solid tumors. The FDA has approved six solid tumor ADCs so far—Sacituzumab govitecan (SG),Read More…
How to Develop ADC in the Future?
ADC has established a solid position in the oncology pharmacopoeia. Over 1,500 clinical trials of ADCs are listed on clinicaltrials.gov, and an increasing number of drugs are entering clinical trials. It canRead More…